Evolent Health (NYSE:EVH) Downgraded by KeyCorp to Sector Weight

Evolent Health (NYSE:EVH) was downgraded by investment analysts at KeyCorp from an “overweight” rating to a “sector weight” rating in a research note issued on Wednesday, Marketbeat Ratings reports.

A number of other research analysts have also weighed in on EVH. JPMorgan Chase & Co. dropped their price objective on Evolent Health from $13.00 to $7.00 and set an “overweight” rating on the stock in a report on Monday, November 17th. BTIG Research decreased their target price on shares of Evolent Health from $16.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Stephens upgraded shares of Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 price target for the company in a report on Thursday, November 13th. Citigroup reduced their price objective on shares of Evolent Health from $9.50 to $6.00 and set a “buy” rating for the company in a research note on Friday, January 9th. Finally, Canaccord Genuity Group decreased their price objective on shares of Evolent Health from $16.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 14th. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.33.

Evolent Health Price Performance

Shares of EVH opened at $2.56 on Wednesday. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 1.25. The stock’s 50 day moving average is $3.54 and its two-hundred day moving average is $5.87. Evolent Health has a twelve month low of $2.52 and a twelve month high of $12.06. The firm has a market capitalization of $285.14 million, a PE ratio of -1.62 and a beta of 0.27.

Hedge Funds Weigh In On Evolent Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC purchased a new stake in shares of Evolent Health in the fourth quarter valued at about $3,927,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Evolent Health by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company’s stock worth $1,217,000 after purchasing an additional 3,572 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Evolent Health by 162.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company’s stock valued at $26,861,000 after buying an additional 1,754,520 shares in the last quarter. Caxton Associates LLP acquired a new stake in Evolent Health during the 1st quarter valued at $252,000. Finally, Strs Ohio acquired a new stake in Evolent Health during the 1st quarter valued at $47,000.

Key Headlines Impacting Evolent Health

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Earnings beat consensus: Evolent reported Q4 EPS of $0.08 vs. the Zacks consensus $0.06, showing an improvement from a loss a year ago — a near-term positive for profitability expectations. Evolent Health (EVH) Q4 Earnings Top Estimates
• Positive Sentiment: Operational growth in specialty area: Management highlighted strong oncology growth and strategic progress during the Q4 earnings call, which supports longer-term revenue diversification. Evolent Health Inc (EVH) Q4 2025 Earnings Call Highlights: Strong Oncology Growth and Strategic …
• Positive Sentiment: Revenue guidance range modestly constructive: The company provided FY?2026 revenue guidance of roughly $2.4B–$2.6B, which overlaps and tops the consensus midpoint — a sign management expects recovery/stability in revenue. Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results
• Positive Sentiment: Analyst sentiment modestly favorable: Coverage shows a consensus recommendation of “Moderate Buy,” supporting demand from some institutional investors. Evolent Health, Inc (NYSE:EVH) Receives Consensus Recommendation of “Moderate Buy” from Analysts
• Neutral Sentiment: Quarter largely in line with expectations: Several summaries describe Q4 results and revenue as roughly in line with street estimates, limiting an outsized surprise. Evolent Health (NYSE:EVH) Reports Q4 CY2025 In Line With Expectations
• Neutral Sentiment: Full disclosures available: Press release, slide deck and call transcript were posted for investors to review details and guidance assumptions. View Press Release / Slide Deck
• Negative Sentiment: Significant YoY revenue decline: Q4 revenue fell ~27.5% year-over-year to $468.7M, and the company reported a negative net margin (~?6.2%), raising concerns about near-term top-line momentum and profitability. Evolent Health Q4 results and metrics
• Negative Sentiment: EPS guidance clarity lacking: Public commentary/filings did not provide clear FY?2026 EPS guidance in the release, which leaves investors with uncertainty about near-term earnings trajectory. Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.